Beta Secretase (BACE) Inhibitors Pipeline Analysis, 2017 by P&S Market Research

GLOBAL INDUSTRY INSIGHT: Beta-Secretase (BACE) Inhibitors Pipeline Analysis, 2017

Global Beta-Secretase (BACE) Inhibitors Pipeline Analysis, 2017

According to a new research report “Beta-Secretase (BACE) Inhibitors Pipeline Analysis, 2017

-

Clinical

Trials

&

Results,

Patent,

Designation,

Collaboration,

and

Other

Developments” published by P&S Market Research, BACE inhibitors currently exhibit a pipeline with estimated 15 drug candidates.

Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/betasecretase-inhibitors-pipeline-analysis The study analyzed that the Beta Secretase inhibitors pipeline comprised 15 drug candidates, of which three products are in Phase III, three products in Phase II, one product in Phase I, and one product is in Discovery. The development of two BACE inhibitor candidates was found to be inactive, and five products were discontinued. BACE is a cleaving enzyme of aspartyl protease with beta-secretase activity. It acts as a precursor of beta-amyloid (Aβ) protein. In Alzheimer’s disease, the Aβ protein fragments get accumulated in plaques in the brain. BACE initiates Aβ production by cleaving amyloid precursor protein (APP) to generate APPβ and C99, which is critical for the subsequent cleavage of C99 by gamma-secretase to release Aβ1-40 and Aβ1-42. Inhibition of BACE enzyme disrupts the production of toxic Aβ and formed plaque and new soluble oligomers.

As per the findings of the research, around 80% pipeline drug candidates of BACE inhibitors are being developed to be administered by oral route and 7% by intravenous route. Most of the therapeutic candidates are being developed to be administered by oral route due to high patient compliance.

Among BACE inhibitors, AZD3293, a drug candidate of AstraZeneca plc and Eli Lilly and Company, received Fast Track designation by the U.S. Food and Drug Administration (FDA) in August 2016.

The FDA’s Fast Track program was designed to expedite the development and review new therapies to treat serious conditions and tackle unmet medical needs.

Browse Report Sample at: https://www.psmarketresearch.com/market-analysis/beta-secretaseinhibitors-pipeline-analysis/report-sample There are three BACE inhibitor drug candidates in the Phase III stage of development.

Lanabecestat is a Phase III stage drug candidate by AstraZeneca plc for the treatment of Alzheimer’s disease. It is a small molecule that inhibits BACE1/2. The drug candidate is administered by oral route. E2609 is under Phase III stage of development by Eisai Co., Ltd. for the treatment of AD. It is a small molecule that inhibits BACE. Eisai Co., Ltd. entered in a collaboration with Biogen Idec for the development and commercialization of E2609, for the

© P&S Market Research. All rights reserved

2

Global Beta-Secretase (BACE) Inhibitors Pipeline Analysis, 2017

treatment of Alzheimer's disease. The agreement also provided Eisai with an option to jointly develop and commercialize two of Biogen Idec's candidates for Alzheimer’s disease - the antiamyloid beta (Aβ) antibody, BIIB037, and an anti-tau monoclonal antibody.

Browse

Other

Related

Report

at:

https://www.psmarketresearch.com/industry-

report/pharmaceuticals Some of the key players developing BACE inhibitors are AstraZeneca plc, Eli Lilly & Company, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Eisai & Co., Ltd., CoMentis, Inc., vTv Therapeutics, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., and Boehringer Ingelheim GmbH.

About P&S Market Research P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact: Kundan Manager – Client Partner 347, 5th Ave. #1402 New York City, NY - 10016 Toll-Free: +1-888-778-7886 (USA/Canada) Email: enquiry@psmarketresearch.com Web: https://www.psmarketresearch.com

© P&S Market Research. All rights reserved

3